Data-driven value demonstration is becoming more and more critical for stakeholders all along the drug development and commercialization journey. This includes financial value, clinical value, and commercial value – meaning effective partnership with CDMOs is increasingly important as their role becomes more intertwined with your commercial plans.
Integrating AI to assist with precise controls, interoperability, and translation of data is a growing element of the best CDMOs, alongside their insight of commercialization and the market.
Jon Williams, Lumanity CEO, spoke to Louis Garguilo, Chief Editor of Outsourced Pharma, giving his view on the new value-driven landscape and what makes an effective CDMO partnership.
